Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

The Associated Press June 9, 2010, 7:48AM ET

Human Genome Sciences says cancer drug fails study

Human Genome Sciences's potential cancer drug mapatumumab failed in a midstage study, the company said Wednesday.

There was no difference in disease response or progression-free survival rates between patients receiving the drug for multiple myeloma and the control group, the company said.

Human Genome Sciences Inc. said it expects to report full results from the study at a scientific meeting later in 2010.

Multiple myeloma is a cancer that affects bone marrow.


BW Mall - Sponsored Links

Buy a link now!